Recent developments in the treatment of age-related macular degeneration

Journal of Clinical Investigation

Volumn 124, Issue 4, 2014, Pages 1430-1438

  Holz, Frank G ^a   Schmitz Valckenberg, Steffen ^a   Fleckenstein, Monika ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN INHIBITOR;

BRUCH MEMBRANE; COMPLEMENT SYSTEM; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTORECEPTOR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

AGED; ANTIBODIES, MONOCLONAL; COMPLEMENT ACTIVATION; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; MACULAR DEGENERATION; OXIDATIVE STRESS; RETINAL PIGMENTS; RETINOIDS; TOXINS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897560418     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71029     Document Type: Review

References (85)

1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738.
2. Campbell JP, Bressler SB, Bressler NM. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol. 2012;130(6):794-795.
3. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153(2):209-213.
4. Belkin M, Kalter-Leibovici O, Chetrit A, Skaat A. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol. 2013;155(2):404.
5. Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol. 2013;91(6):540-546.
6. Singer MA, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175-1183.
7. Rofagha S, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292-2299.
8. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye (Lond). 1988;2(pt 5):552-577. (Pubitemid 19142671)
9. Green WR, Key SN 3rd. Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc. 1977;75:180-254.
10. Yannuzzi LA, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21(5):416-434. (Pubitemid 32971350)
11. Thumann G, Dou G, Wang Y, Hinton DR. Cell biology of the retinal pigment epithelium. In: Ryan SJ, ed. Retina. London, United Kingdom: Elsevier; 2013:401-414.
12. Booij JC, Baas DC, Beisekeeva J, Gorgels TG, Bergen AA. The dynamic nature of Bruch's membrane. Prog Retin Eye Res. 2010;29(1):1-18.
13. Fritsche LG, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45(4):433-439.
14. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-1436.
15. Chew EY, et al. Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmol. 2013;131(7):843-850.
16. Christen WG, Schaumberg DA, Glynn RJ, Buring JE. Dietary Eω-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch Ophthalmol. 2011;129(7):921-929.
17. Schleicher M, Weikel K, Garber C, Taylor A. Diminishing risk for age-related macular degeneration with nutrition: a current view. Nutrients. 2013;5(7):2405-2456.
18. Boulton M. Ageing of the retina and retinal pigment epithelium. In: Holz FG, Pauleikhoff D, Spaide RF, Bird AC, eds. Age-Related Macular Degeneration. Heidelberg, Germany: Springer; 2013:45-63.
19. Suter M, et al. Age-related macular degeneration. The lipofusion component N-retinyl-N-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. J Biol Chem. 2000;275(50):39625-39630. (Pubitemid 32058989)
20. Palczewska G, et al. Noninvasive multiphoton fluorescence microscopy resolves retinol and retinal condensation products in mouse eyes. Nat Med. 2010;16(12):1444-1449.
21. Schmitz-Valckenberg S, Fleckenstein M, Scholl HP, Holz FG. Fundus autofluorescence and progression of age-related macular degeneration. Surv Ophthalmol. 2009;54(1):96-117.
22. Grossniklaus HE, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8:119-126. (Pubitemid 36153599)
23. Cherepanoff S, McMenamin P, Gillies MC, Kettle E, Sarks SH. Bruch's membrane and choroidal macrophages in early and advanced agerelated macular degeneration. Br J Ophthalmol. 2010;94(7):918-925.
24. Lutty G, Bhutto I, Seddon J, McLeod D. Mast cell degranulation in AMD choroid. Invest Ophthalmol Vis Sci. 2013;54(6):3051.
25. Ebrahimi KB, Handa JT. Lipids, lipoproteins, and age-related macular degeneration. J Lipids. 2011;2011:802059.
26. Hecker LA, et al. Genetic control of the alternative pathway of complement in humans and agerelated macular degeneration. Hum Mol Genet. 2010;19(1):209-215.
27. Loyet KM, et al. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53(10):6628-6637.
28. Haines JL, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308(5720):419-421. (Pubitemid 40530081)
29. Klein RJ, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385-389. (Pubitemid 40530070)
30. Hageman GS, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102(20):7227-7232. (Pubitemid 40696361)
31. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308(5720):421-424. (Pubitemid 40530082)
32. Maller J, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet. 2006;38(9):1055-1059. (Pubitemid 44325932)
33. Gold B, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38(4):458-462.
34. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007;39(10):1200-1201. (Pubitemid 47482689)
35. Yates JR, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357(6):553-561. (Pubitemid 47236280)
36. Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, Seddon JM. Variation near complement factor I is associated with risk of advanced AMD. Eur J Hum Genet. 2009;17(1):100-104.
37. Fritsche L, Friedrich U, Weber BH. Genetics. In: Holz FG, Pauleikhoff D, Spaide RF, Bird AC, eds. Age-Related Macular Degeneration. Heidelberg, Germany: Springer; 2013:33-43.
38. Giannakis E, et al. Multiple ligand binding sites on domain seven of human complement factor H. Int Immunopharmacol. 2001;1(3):433-443. (Pubitemid 32197542)
39. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol. 2004;41(4):355-367. (Pubitemid 38639887)
40. Nitsch D, Douglas I, Smeeth L, Fletcher A. Age-related macular degeneration and complement activation-related diseases: a population-based case-control study. Ophthalmology. 2008;115(11):1904-1910.
41. Raychaudhuri S, et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet. 2011;43(12):1232-1236.
42. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37(5):855-868.
43. Tong JP, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141(3):456-462.
44. Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M, Miller SS. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Ophthalmol Vis Sci. 2003;44(2):781-790. (Pubitemid 36159730)
45. Krzystolik MG, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120(3):338-346. (Pubitemid 34250056)
46. Grisanti S, Lüke J, Peters S. Anti-VEGF therapy: basics and substances. In: Holz FG, Pauleikhoff D, Spaide RF, Bird AC, eds. Age-Related Macular Degeneration. Heidelberg, Germany: Springer; 2013:225-232.
47. Nishijima K, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171(1):53-67. (Pubitemid 47339226)
48. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A. 2009;106(44):18751-18756.
49. Barakat M, Steinle N, Kaiser PK. Combination therapies for treatment of AMD. In: Holz FG, Pauleikhoff D, Spaide RF, Bird AC, eds. Age-Related Macular Degeneration. Heidelberg, Germany: Springer; 2013.
50. Mitchell P, Foran S. Anti-VEGF therapy for AMD: results and guidelines. In: Holz FG, Pauleikhoff D, Spaide RF, Bird AC, eds. Age-Related Macular Degeneration. Heidelberg, Germany: Springer; 2013.
51. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45(3):195-214.
52. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816. (Pubitemid 40051904)
53. Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. (Pubitemid 44511557)
54. Brown DM, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444. (Pubitemid 44511558)
55. Martin DF, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
56. Busbee BG, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-1056.
57. Lalwani GA, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58.
58. Holz FG, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663-671.
59. Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf. 2010;9(1):149-165.
60. Pelle G, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis. 2011;57(5):756-759.
61. Ohr M, Kaiser PK. Aflibercept in wet age-related macular degeneration: a perspective review. Ther Adv Chronic Dis. 2013;3(4):153-161.
62. Heier JS, et al. Intravitreal aflibercept (VEGF trapeye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
63. Sivaprasad S, et al. Retrospective analysis of the real-world utilization of ranibizumab in wAMD. Invest Ophthalmol Vis Sci. 2013;54(6):3836.
64. Chakravarthy U, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-1411.
65. Chakravarthy U, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-1267.
66. El Sanharawi M, Kowalczuk L, Touchard E, Omri S, de Kozak Y, Behar-Cohen F. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog Retin Eye Res. 2010;29(6):443-465.
67. Stahl A, et al. Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis. 2013;16(1):101-111.
68. Wolf S, et al. Phase I Mp0112 wet AMD study: results of a single escalating dose study with DARPin(R) MP0112 in wet AMD. Invest Ophthalmol Vis Sci. 2011;52(6):1655.
69. Boyer D. A phase 2b study of fovista & trade; a platelet derived growth factor (PDGF) inhibitor in combination with a vascular endothelial growth factor (VEGF) inhibitor for neovascular age-related Macular Degeneration (AMD). Invest Ophthalmol Vis Sci. 2013;54(6):2175.
70. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114(2):253-262. (Pubitemid 46161820)
71. Radu RA, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscinbased retinal diseases. Invest Ophthalmol Vis Sci. 2005;46(12):4393-4401. (Pubitemid 44264531)
72. Mata NL, Lichter JB, Vogel R, Han Y, Bui TV, Singerman LJ. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina. 2013;33(3):498-507.
73. Zhao C, et al. mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. J Clin Invest. 2011;121(1):369-383.
74. Wong WT, et al. Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci. 2013;54(4):2941-2950.
75. Holz F. The MAHALO Phase II Study: Safety, Tolerability and Evidence of Activity of Lampalizumab (Anti-factor D) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). Paper presented at: 13th Euretina Congress; September 27, 2013; Hamburg, Germany.
76. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009;373(9665):759-767.
77. Yehoshua Z, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: The COMPLETE study of ophthalmology. Ophthalmology. 2013;S0161-6420(13)00889-0.
78. LaVail MM, et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci. 1998;39(3):592-602. (Pubitemid 28110693)
79. Cayouette M, Behn D, Sendtner M, Lachapelle P, Gravel C. Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse. J Neurosci. 1998;18(22):9282-9293. (Pubitemid 28512459)
80. Zhang K, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(15):6241-6245.
81. Collier RJ, et al. Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress. Invest Ophthalmol Vis Sci. 2011;52(5):2118-2126.
82. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003;48(suppl 1):S47-S51. (Pubitemid 41126695)
83. Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol. 2009;127(4):402-406.
84. Schwartz SD, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379(9817):713-720.
85. Smailhodzic D, et al. Central areolar choroidal dystrophy (CACD) and age-related macular degeneration (AMD): differentiating characteristics in multimodal imaging. Invest Ophthalmol Vis Sci. 2011;52(12):8908-8918.